Cannabis is moving toward pharmaceutical cannabis, meaning formal research, pharmacy distribution, hospital use, and insurance coverage, which lowers cost and raises access by shifting it from weed shop to medicine.
If that shift happens, not all companies win; the early winners are the ones already built like medical operators, and MariMed fits that profile with established patient products, multi state operations, low debt, and a focus on medical demand instead of hype.
Odds favor rescheduling because the DEA, FDA, and lawmakers are already aligned in that direction, and if it happens, pharmaceutical cannabis companies like MariMed benefit first because they are already operating as if the rules have changed.
AI
Market Data 
Markets 
